5-HT-moduline, a 5-HT(1B/1D) receptor endogenous modulator, interacts with dopamine release measured in vivo by microdialysis
5-Hydroxytryptamine-moduline (5-HT-moduline) is an endogenous tetrapeptide (Leu-Ser-Ala-Leu) recently isolated and characterized from mammalian brain. This compound interacts with 5-HT1B receptors as a non-competitive, high-affinity antagonist and has the properties of an allosteric modulator. 5-HT-...
Saved in:
Published in | European journal of pharmacology Vol. 358; no. 2; p. 129 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
02.10.1998
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | 5-Hydroxytryptamine-moduline (5-HT-moduline) is an endogenous tetrapeptide (Leu-Ser-Ala-Leu) recently isolated and characterized from mammalian brain. This compound interacts with 5-HT1B receptors as a non-competitive, high-affinity antagonist and has the properties of an allosteric modulator. 5-HT-moduline could play an important role in the regulation of serotonergic transmission and also, through heteroreceptors, dopaminergic transmission. The aim of this work was to examine the potential ability of 5-HT-moduline to modify the basal extracellular concentration of dopamine and its metabolites (3-methoxytyramine, dihydroxyphenylacetic acid and homovanillic acid), in the rat striatum and to determine its potential interaction with the stimulating activity of a specific 5-HT1B receptor agonist, 3-(1,2,5,6-tetrahydropyrid-4-yl) pyrrolo [3,2-b] pyrid-5-one (CP-93,129), on the release of dopamine. The technique is based on in vivo microdialysis using probes implanted in the striatum of the conscious rat. Results showed that the perfusion of 5-HT-moduline directly into this structure (1.25 mM) increased the striatal level of dopamine by two-fold (104% of the absolute basal release values, P = 0.0015) and that of 3-methoxytyramine by 3-fold (293%, P = 0.0001) without any change in the terminal metabolite concentrations. The intrastriatal administration of CP-93,129 induced a statistically significant, dose-dependent increase of dopamine levels (P < 0.0001). Coperfusion of 5-HT-moduline did not significantly alter the effect of CP-93,129 at 0.1 and 0.5 mM, but appeared to have an additive effect on the lowest dose (P = 0.0406). The results obtained show that 5-HT-moduline directly administered into the striatum increases the release of dopamine in this area. Presumably, this effect results from the desensitization of 5-HT1B receptors located on dopamine terminals. However, the fact that a 5-HT1B receptor agonist (CP-93,129) also increased the release of dopamine in the striatum and that 5-HT-moduline exhibited a slight additive effect with that of a low concentration of CP-93,129 suggests that the two substances interact with different mechanisms. |
---|---|
AbstractList | 5-Hydroxytryptamine-moduline (5-HT-moduline) is an endogenous tetrapeptide (Leu-Ser-Ala-Leu) recently isolated and characterized from mammalian brain. This compound interacts with 5-HT1B receptors as a non-competitive, high-affinity antagonist and has the properties of an allosteric modulator. 5-HT-moduline could play an important role in the regulation of serotonergic transmission and also, through heteroreceptors, dopaminergic transmission. The aim of this work was to examine the potential ability of 5-HT-moduline to modify the basal extracellular concentration of dopamine and its metabolites (3-methoxytyramine, dihydroxyphenylacetic acid and homovanillic acid), in the rat striatum and to determine its potential interaction with the stimulating activity of a specific 5-HT1B receptor agonist, 3-(1,2,5,6-tetrahydropyrid-4-yl) pyrrolo [3,2-b] pyrid-5-one (CP-93,129), on the release of dopamine. The technique is based on in vivo microdialysis using probes implanted in the striatum of the conscious rat. Results showed that the perfusion of 5-HT-moduline directly into this structure (1.25 mM) increased the striatal level of dopamine by two-fold (104% of the absolute basal release values, P = 0.0015) and that of 3-methoxytyramine by 3-fold (293%, P = 0.0001) without any change in the terminal metabolite concentrations. The intrastriatal administration of CP-93,129 induced a statistically significant, dose-dependent increase of dopamine levels (P < 0.0001). Coperfusion of 5-HT-moduline did not significantly alter the effect of CP-93,129 at 0.1 and 0.5 mM, but appeared to have an additive effect on the lowest dose (P = 0.0406). The results obtained show that 5-HT-moduline directly administered into the striatum increases the release of dopamine in this area. Presumably, this effect results from the desensitization of 5-HT1B receptors located on dopamine terminals. However, the fact that a 5-HT1B receptor agonist (CP-93,129) also increased the release of dopamine in the striatum and that 5-HT-moduline exhibited a slight additive effect with that of a low concentration of CP-93,129 suggests that the two substances interact with different mechanisms. |
Author | Massot, O Reymann, J M Bentué-Ferrer, D Rousselle, J C Bourin, M Fillion, G Allain, H |
Author_xml | – sequence: 1 givenname: D surname: Bentué-Ferrer fullname: Bentué-Ferrer, D organization: Laboratoire de Pharmacologie, Faculté de Médecine, Rennes, France – sequence: 2 givenname: J M surname: Reymann fullname: Reymann, J M – sequence: 3 givenname: J C surname: Rousselle fullname: Rousselle, J C – sequence: 4 givenname: O surname: Massot fullname: Massot, O – sequence: 5 givenname: M surname: Bourin fullname: Bourin, M – sequence: 6 givenname: H surname: Allain fullname: Allain, H – sequence: 7 givenname: G surname: Fillion fullname: Fillion, G |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/9808261$$D View this record in MEDLINE/PubMed |
BookMark | eNo9kE1PAjEURbvAIKA_gaRLSKi00w_apeIHJiQuxMQd6bRFa2amk-kMZhb-d6sSN-8l5553F28MBlWoHABTgq8IJmL5jDFhKFNKzZScY8ylQK8DMPrH52Ac4wdOicr4EAyVxDITZAS-ONrsUBlsV_jKLaCGP2BGbpbkdg4bZ1zdhga6yoY3V4Uuwl9XJ7iAvmpdo00b4adv36ENtS5TSzornI4Olml2jbNJhEd_DDDvYelNE6zXRR99vABnB11Ed3naE_Byf7dbb9D26eFxfb1FNclIizjh2rGDFivFlJSMCUMPSriVtRQbkVmhcc5FnnFjpKB5siw3lHFmiLWc0gmY_vXWXV46u68bX-qm35_eQL8B3VpgXA |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1016/S0014-2999(98)00586-X |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
ExternalDocumentID | 9808261 |
Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
GroupedDBID | --- --K --M -~X .55 .GJ .~1 0R~ 1B1 1RT 1~. 1~5 29G 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXKI AAXLA AAXUO ABCQJ ABFNM ABFRF ABJNI ABMAC ABZDS ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD AEFWE AEKER AENEX AFKWA AFTJW AFXIZ AGUBO AGWIK AGYEJ AHHHB AIEXJ AIKHN AITUG AJOXV AKRWK ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC CGR CS3 CUY CVF DU5 EBS ECM EFJIC EIF EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q HMQ HVGLF HZ~ IHE J1W K-O KOM L7B M2V M34 M41 MO0 MOBAO N9A NPM O-L O9- OAUVE OGGZJ OVD OZT P-9 P2P PC. Q38 R2- RIG ROL RPZ SDF SDG SDP SES SNS SPCBC SPT SSN SSP T5K TEORI X7M ZGI ~G- |
ID | FETCH-LOGICAL-p121t-515ae4fa6794988446c3f96e7dd30c62d6a0b56b25cc863b949d5c3454c1dd533 |
ISSN | 0014-2999 |
IngestDate | Sat Sep 28 08:39:05 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p121t-515ae4fa6794988446c3f96e7dd30c62d6a0b56b25cc863b949d5c3454c1dd533 |
PMID | 9808261 |
ParticipantIDs | pubmed_primary_9808261 |
PublicationCentury | 1900 |
PublicationDate | 1998-Oct-02 |
PublicationDateYYYYMMDD | 1998-10-02 |
PublicationDate_xml | – month: 10 year: 1998 text: 1998-Oct-02 day: 02 |
PublicationDecade | 1990 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | European journal of pharmacology |
PublicationTitleAlternate | Eur J Pharmacol |
PublicationYear | 1998 |
SSID | ssj0005925 |
Score | 1.7261665 |
Snippet | 5-Hydroxytryptamine-moduline (5-HT-moduline) is an endogenous tetrapeptide (Leu-Ser-Ala-Leu) recently isolated and characterized from mammalian brain. This... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 129 |
SubjectTerms | Animals Brain - drug effects Brain - metabolism Dopamine - metabolism Drug Interactions Male Microdialysis Neuropeptides - pharmacology Oligopeptides - pharmacology Pyridines - pharmacology Pyrroles - pharmacology Rats Rats, Sprague-Dawley Receptor, Serotonin, 5-HT1B Receptor, Serotonin, 5-HT1D Receptors, Serotonin - drug effects Serotonin Receptor Agonists - pharmacology |
Title | 5-HT-moduline, a 5-HT(1B/1D) receptor endogenous modulator, interacts with dopamine release measured in vivo by microdialysis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/9808261 |
Volume | 358 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swEBZZx6AvY7_Ktm5DD6O0JGprW5Ktx7VdCYNupUshb0WyFNiDY9M6hRS2_2T_6-4sxXa7Fba9mES2ZaP7kO47674j5H1kXGaSVDAXG8dghU4YUDCUceVSK8x0bBKFTz7L8Tn_NBXTweBnb9fSoja7-c0f80r-x6rQBnbFLNl_sGzbKTTAb7AvHMHCcPwrGws2nrCitAsvF3o41ENsQu2lA-TKR8j5YUpzVY3C3nNbBknW5h5de6qOihGYKxUS3SzQ6AJ9TyynAmvcsPBhRBRpGl5_uy7RYy1wHx_mnKCgyb3R_eDpVp08dpc-gYud_0rPjt1lKKrdbj8-c8tiVb65C9iewbtf4ZcG394GeE-AAZTNavKli2I0aX34Db4f2ASqxmBpVP2ZORFZD4Jxb56NfJjkt_nfhyK-tr3BgKsMxhqrJ0o27d8DpqyKBhgqAz_IS8Lf0d4OZx6Qh3GqBHL73R-9HUQqDgUy_MO6BLG97g22VbYTnr5OHoUO73CYxpeZPCGPAwmhHzyinpKBmz8jW6feTMsRnXRJeVcjukVPewZ8Tr7fgt2IaooN29HBXnS0Q1dwox3caAu3EW3BRhFsdAU2GsBGV2CDCymCjZolvQW2F-T8-OPkcMxCFQ9WRXFUM3CYteMzLWHmV1nGucyTmZIutTbZz2Vspd43QppY5HkmEwNXWZEnXPA8shbYyAZZm5dz95LQ1IHvpKXUMyl5Bn9gebIyBYpikiTn8hXZ8MN6UXmplosw3q_vO7FJ1js0viFr9eXCvQUvszbvGlv_ApQxduM |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=5-HT-moduline%2C+a+5-HT%281B%2F1D%29+receptor+endogenous+modulator%2C+interacts+with+dopamine+release+measured+in+vivo+by+microdialysis&rft.jtitle=European+journal+of+pharmacology&rft.au=Bentu%C3%A9-Ferrer%2C+D&rft.au=Reymann%2C+J+M&rft.au=Rousselle%2C+J+C&rft.au=Massot%2C+O&rft.date=1998-10-02&rft.issn=0014-2999&rft.volume=358&rft.issue=2&rft.spage=129&rft_id=info:doi/10.1016%2FS0014-2999%2898%2900586-X&rft_id=info%3Apmid%2F9808261&rft.externalDocID=9808261 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-2999&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-2999&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-2999&client=summon |